Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2B Randomised, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of MIS416 in the Treatment of Subjects With Secondary Progressive Multiple Sclerosis

NCT02228213 is registered in ClinicalTrials.gov with Innate Immunotherapeutics as lead sponsor.

NCT NCT02228213
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02228213 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2B Randomised, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of MIS416 in the Treatment of Subjects With Secondary Progressive Multiple Sclerosis
Lead sponsor
Innate Immunotherapeutics
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2014
Completion date
June 30, 2017
Enrollment
93 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

secondary progressive multiple sclerosis